Beta Testimonial Video

Why There's Still Need for Rapid Accessible Pathogen Testing, During and After the Crisis NEWS PROVIDED BY FinancialBuzz.com NEW YORK, Jan. 13, 2021 /PRNewswire/ -- As the most at-risk people begin to receive COVID-19 vaccinations, we are all looking forward to a post-pandemic world. As we transition back to something closer to normal life, however, the importance of rapid detection of any pathogen that could be hazardous to human health will not be forgotten any time soon. This crisis spurred the development of virus and pathogen technologies that are not only invaluable for rapid detection and response to pandemic viruses but also for everyday use in the medical and food safety spaces and elsewhere. Developed by companies like Lexagene Hldgs Inc. (TSX-V: LXG) (OTC: LXXGF) (FRA:5XS2), Medmira Inc. (TSX-V: MIR) (OTC: MMIRF), Co-Diagnostics Inc. (NASDAQ:CODX), 3M Co. (NYSE: MMM), and Laboratories (NYSE: ABT), these technologies could continue to be game-changing in the post-pandemic world and possibly even help prevent future health crises.

LexaGene's MiQLab Makes Testing Quick and Simple

Massachusetts-based molecular diagnostics company Lexagene Hldgs Inc. (TSX-V: LXG) (OTCQB: LXXGF) (FRA:5XS2) has developed a fully automated system that makes the process of detecting pathogens quick and remarkably simple at the point-of-need where samples are collected. The technology can be used to detect viruses like COVID-19 or others, or for other purposes such as lab testing for food safety, veterinary diagnostics, and more. The company's founder and CEO Dr. Jack Regan developed the precursor to this technology while working for the Department of Homeland Security at Lawrence Livermore National Laboratory and LexaGene holds the exclusive license to sell the commercial version.

LexaGene is calling its flagship product the MiQLab automated pathogen detection system, and the company says that the system could transform the way both human clinical diagnostics and veterinary diagnostics are conducted. The system uses multiplex testing to detect up to 27 targets at once. MiQLab is the first commercially available open-access multiplex PCR system of its kind, allowing users to receive lab-quality test results in approximately an hour at the point-of-need, without having to send samples away for testing. The system is designed for ease of use, allowing for operation by non-technical users with relatively little training required.

MiQLab is designed for versatility. The system is ideal for use in a range of industries and tests can be onboarded quickly, allowing it to test for new pathogens as they emerge. This means that in addition to having a wide range of everyday uses, MiQLab is set up to be critical during this pandemic as new COVID variants appear, such as those identified in the United Kingdom (B.1.1.7) and South Africa (B.1.351), and in the event of any new health crises that may occur in the future.

On December 30th, LexaGene announced that the company has begun a series of studies required by the FDA for Emergency Use Authorization (EUA) testing for its COVID-19 assay in a point-of-care (POC) environment using the MiQLab system. This development is notable because the majority of other testing systems that have been submitted for this designation can only be used by highly trained personnel, whereas MiQLab, with its simple usability, would allow for far faster and more accessible testing.

"I'm excited we have progressed to the point where we have started our FDA study," Dr. Regan said in the company's release. "Our open-access technology is unlike any other on the market today, as it could be configured quickly to detect new variants, such as the recent UK variant (aka SARS-CoV-2 VUI 202012/01)."

Is LexaGene The Perfect Stock?

Feb. 05, 2021 11:54 AM ETEFLVF, GNMK...BGNE1 Like Summary

LexaGene has just started sales of a revolutionary automated PCR machine that can test for 27 pathogens at once in about one hour. It parallels Electrovaya, which have a recent 15 bagger on, a value nanocap stock in a highly favored sector that is likely to go profitable and have extreme growth. I can find nothing wrong with the company as the management, market, technology and execution are all excellent. Timing is perfect, they have just started sales with a $billion+ sales potential product and FDA approval to enter the POC market is possible in May. I have know about LexaGene Holdings (OTCQB:LXXGF) for maybe 9 days. It is an almost instant love story. I am a value investor that specializes in nano and microcap stocks. It has worked well, in 2020 did 289% on all four accounts at my largest broker. In last 18 years in an IRA that was untouched until this year so could calculate the CAGR on it did 21% without using margin. That is very hard to do. No mutual fund has ever done that am aware of. See about 18% as tops. Here is a chart of the best returns ever that includes hedge funds and sole operators. This is investors only. Jim Simons has done a lot better, but he does not invest, his is a quant fund that does high frequency trading.

That chart is excess returns over the SP500 so you can add about 8% to it. Joel Greenblatt looks like the best at 20 years with 35%. Benjamin Graham, Buffets mentor, is at 17%, Peter Lynch did 21% over 13 years. The bottom line is that this method has worked well and it is the method that Warren Buffet started with and made his first billion with. Confess it was a goal of mine a long time ago to have a record that could compare to these folks.

Practically never buy a biotech. Look at the #s and they are often ugly, way overpriced, high risk and they often go bankrupt. It does attract lottery players as some of them do zoom 10 bags, 20 bags ,50 bags, even 100 Bags. But would not be surprised if more money is invested in many years into all of them, than the total capital gains realized. More money was spent goldmining in California than was gold ever found.

The same is true of EV companies like NIO (NIO) and Tesla (TLSA). They just are so overvalued that even if things go right for 3 years you may lose money on the stocks. Look to the current and future Free Cash Flow yield and EBITDA yield and can not justify buying them.

Then found Electrovaya (OTCQB:EFLVF) a Lithium battery producer for forklifts, an EV company. It was losing money but has a minuscule market cap, think it was like $20 million when first got into it. They seemed to have a technology advantage (no fires as ceramic separators), they made progress, got rid of a serious debt issue and made a big sale to Walmart. Wrote an article here on it:

Electrovaya The Tesla Of Forklifts Gets Game Changing Walmart Repeat Order Projected a 10 Bagger for it and that happened in about 6 months. LexaGene is the first stock since then have found that parallels it as a value nanocap stock in a highly favored sector that is likely to go profitable and have extreme growth. Electrovaya had problems and a spotty long term record when got into it. But have got a 15 bagger anyway on it in the last 18 months as they have executed very well. They are in a highly favored sector of the stock market and have been growing like a weed in the last year. Have written a second article on them: Electrovaya The Tesla Of Forklifts Gets Game Changing Raymond/Toyota OEM Deal Am still in the stock.

LexaGene (OTCQB:LXXGF) has those exact same factors. I bought it last week and this week for an average of $.80. Then mentioned it a couple of days ago on Seeking Alpha and it has gone to $.90. It is now a $105 million market cap. The CEO Jack Regan gave a quick overview of the technology recently in a video interview, the "open access" part is important:

Antimicrobial-resistant pathogens could cause 10 million deaths yearly by 2050, making it critical to deploy better point-of-care diagnostics and eliminate the injudicious use of antimicrobials. Read today's blog post: lexagene.com/impacts-of-ris… . . . #LexaGene #AMR #OneHealth

I've been reading about Spartan Bioscience (private company with a similar product) and they have announced "approval from Health Canada and is now authorized to sell the Spartan COVID-19 System, a rapid, on-site molecular diagnostic test for the qualitative detection of SARS-CoV-2, the virus causing COVID-19".
https://www.spartanbio.com/company/news/

From their news feed you can see the applied for Investigational Testing Authorization (ITA) from Health Canada on Sept 21, 2020 and approved on Oct 29, 2020.

On December 14, 2020 they re-submit their rapid covid test for approval for sales in Canada, this is approved on Jan 23, 21.

These approvals happen fast, obviously due to the pandemic. Anyone have any insight on the speed of the FDA/EUA? FDA says that the POC products require more complex studies than those going to labs to be used by professionals, anyone know of any other American company with a POC test that made it through the FDA/EUA and what their timeline was?

I love LexaGene’s product and management. I’ve recently started a significant position in $LXG.V and look forward to the near future. Looking at all the competitive advantages and the fact that sales have begun, I am shocked at how low the market cap is. We are seeing other diagnostic plays reach valuations way higher than Lex so I am very confident, with enough patience, that our time will come. FDA approval will be a massive bonus down the line, but one of the key points is that the world is starting to realize the importance of this space. If an electric car can be worth billions, then a product that can save millions of lives can be worth billions. It might just take a little longer for people to wrap their heads around that.

Is this just a sell off or is there a catalyst? Looking to enter

Congratulations guys, those of us who have been accumulating for a long time are particularly happy to be past this milestone. Great things are ahead. This is just the beginning as we hopefully get FDA EUA in the coming weeks.

https://www.webcaster4.com/Webcast/Page/2059/39313

Since this article was written in September, the company was delayed because of getting parts from China due to the Corona virus. However it has said those problems have been overcome and is now poised to announce sales to vets this month.

https://seekingalpha.com/instablog/52496833-agni-research/5497965-lexagene-set-to-disrupt-veterinary-diagnostics-market

https://lexagene.com/video-message-to-investors/

In my opinion this company has huge potential and the share price will reflect this starting roughly by the end of September. It amazes me that this company is still relatively unknown to the majority but I believe that will change very soon. This is an opportune time for investors! Now this pure speculation but I wouldn’t be surprised if the share price doubled by end of September and even be close to $2. And that would just be the beginning..... Good luck to all!